Anthony Moorman, PhD, on ALL: Improving Outcomes With a Tyrosine Kinase Inhibitor Plus Chemotherapy
Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may have improved outcomes when a tyrosine kinase inhibitor is added to chemotherapy (Abstract S117).
Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, with promising efficacy in heavily pretreated patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Clinical follow-up, correlative biomarker analysis, and expansion cohort enrollment to assess discontinuous dosing are underway (Abstract S116).
Andrew H. Wei, MBBS, PhD, of The Alfred Hospital, Monash University, discusses phase III data from the VIALE-C trial, which appear to support the use of venetoclax plus low-dose cytarabine as a front-line treatment for older patients with acute myeloid leukemia, as well as for those who cannot tolerate intensive chemotherapy (Abstract S136).
Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphamide, vincristine, and prednisolone is a feasible and effective regimen for front-line treatment of high-risk patients with diffuse large B-cell lymphoma who are not eligible for standard chemotherapy (Abstract S232).
Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes compared with intensive chemotherapy in older patients with acute myeloid leukemia, with benefits most pronounced in people at high risk of treatment-related mortality (Abstract S141).
Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myeloid leukemia who are ineligible for intensive therapy. The research shows venetoclax plus azacitidine improved response rates and overall survival compared with azacitidine alone (Abstract LB2601).